Amarin Corp Shs Sponsored American Deposit Receipt Repr 1 Sh $1.80

down 0.00


31/7/2014 04:00 PM  |  NASDAQ : AMRN  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get AMRN Trend Analysis - it has underperformed the S&P 500 by 82%

Partner Headlines

  1. Amarin Moves Higher On Speculation Of Special Protocol Assessment

    Benzinga
  2. Top Performing Industries For June 12, 2014

    Benzinga
  3. FDA Approvals And Changes For The Week Ending February 14, 2014

    Benzinga
  4. Amarin Announces FDA DMEP Does Not Plan to Re-instate ANCHOR SPA Agreement

    Benzinga
  5. Benzinga's Top #PreMarket Losers

    Benzinga
  6. Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement Reinstatement ...

    Benzinga
  7. FDA Delays Decision on Amarin's Vascepa Drug

    Benzinga
  8. Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will ...

    Benzinga
  9. Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

    Benzinga
  10. Amarin Announces Notification of Patent Allowances Related to Triglyceride ...

    Benzinga
  11. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  12. Is Amarin’s Fish Oil Blockbuster Dream Kaput?

    YCharts
  13. UPDATE: Citigroup Upgrades Amarin on Valuation

    Benzinga
  14. Benzinga's Top Upgrades

    Benzinga
  15. Aegis Capital Corp. Reiterates on Amarin Corporation plc After FDA Formally ...

    Benzinga
  16. Market Wrap For Thursday, October 17: S&P Record High On Debt Deal

    Benzinga
  17. Mid-Day Market Update: SanDisk Surges On Upbeat Results; IBM Shares Tumble

    Benzinga
  18. Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Revenue Drops ...

    Benzinga
  19. Stocks Hitting 52-Week Lows

    Benzinga
  20. UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel Vote on ...

    Benzinga
  21. Benzinga's Top Pre-Market Losers

    Benzinga
  22. Amarin Announces Negative FDA Advisory Committee Outcome for the Use of ...

    Benzinga
  23. Amarin Halted Ahead of FDA Advisory Committee to Review sNDA for Vascepa( ...

    Benzinga
  24. Aegis Says FDA's Outlook 'Not As Negative As People Think' on Amarin

    Benzinga
  25. Aegis Capital Reiterates Buy on Amarin Corporation Following Release of ...

    Benzinga
  26. Jefferies Reiterates Buy on Amarin Corporation on Continued Positive Outlook

    Benzinga
  27. Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory Panel

    Benzinga
  28. Amarin Shares Up 5% as FDA Says October 16th Advisory Committee Meeting ...

    Benzinga
  29. Enrollment in Amarin REDUCE-IT Cardiovascular Outcomes Study Surpasses ...

    Benzinga
  30. Amarin Reports 30th Patent for Vascepa

    Benzinga
  31. Amarin Submits Supplemental NDA for Novasep as Fourth Vascepa Active Pharmaceutical ...

    Benzinga
  32. UPDATE: Citigroup Raises PT on Amarin Following Lighter 2Q13 Sales

    Benzinga
  33. UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion

    Benzinga
  34. Amarin Announces USPTO Allowance for Application 13/614,129 Related to ...

    Benzinga
  35. Amarin Announces Patent Allowance Related to Vascepa and FDA Approved MARINE ...

    Benzinga
  36. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  37. Benzinga's Top Pre-Market Gainers

    Benzinga
  38. Amarin Completes Dosing in a Fixed-Dose Combination Study With Vascepa ...

    Benzinga
  39. Amarin Closes Dosing in Fixed-Dose Combination Study with Vascepa

    Benzinga
  40. FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status in November ...

    Benzinga
  41. Benzinga's Top Pre-Market Gainers

    Benzinga
  42. Amarin Receives Patent Allowance for Application 13/623,450 Related to ...

    Benzinga
  43. Amarin Announces David Stack Appointed to Board of Directors

    Benzinga
  44. Amarin Spikes Lower

    Benzinga
  45. UDPATE: Aegis Capital Raises PT on Amarin to $35

    Benzinga
  46. Citigroup Reiterates Buy Rating, $20 PT on Amarin Corporation

    Benzinga
  47. Benzinga's Top Pre-Market Losers

    Benzinga
  48. UPDATE: Citigroup Initiates Amarin at Buy on Vascepa Overhang Removal

    Benzinga
  49. Benzinga's Top Pre-Market Gainers

    Benzinga
  50. Amarin Awarded Patent 8,318,715 for Vascepa by USPTO

    Benzinga
Trading Center